News

November 26, 2018

Phase 1 Study of BTK Inhibitor in Treating B-cell Blood Cancers Underway, TG Therapeutics Announces

News

A Phase 1 clinical trial, sponsored by TG Therapeutics, is recruiting patients with B-cell lymphoma or leukemia to study the company’s Bruton tyrosine kinase (BTK) inhibitor, TG-1701. The study is enrolling ... Read more

November 20, 2018

Adcetris-Chemo Combo Gets FDA Approval for First-line Treatment of PTCL

News

The U.S. Food and Drug Administration (FDA) approved Seattle Genetics‘ application requesting that Adcetris (brentuximab vedotin) be used in combination with chemotherapy as a first-line treatment for systemic anaplastic large ... Read more

November 16, 2018

Opdivo Plus ASCT Ably Treats Classical Hodgkin’s Lymphoma Patients with Few Options, Study Says

News

Classical Hodgkin’s lymphoma patients who failed to respond to autologous stem cell transplant (patient-derived cells) showed “unprecedented” low relapse rates after being given Opdivo (nivolumab) followed by an allogeneic, or ... Read more

November 14, 2018

Verastem Advances Copiktra for Peripheral T-cell Lymphoma Under LLS Therapy Acceleration Program

News

Aiming to accelerate the development of Copiktra (duvelisib) for treatment of peripheral T-cell lymphoma (PTCL) — an aggressive type of non-Hodgkin’s lymphoma — Verastem has announced a collaboration with the Leukemia & Lymphoma ... Read more

November 13, 2018

Rituxan Shows Similar Benefit With or Without Chemo in Indolent Lymphomas, Study Finds

News

Using Rituxan (rituximab) as first-line treatment for indolent — or slow-growing — lymphomas leads to similar long-term survival as regimens containing both Rituxan and chemotherapy, a study shows. The approach also ... Read more

November 12, 2018

FDA Gives Selinexor Fast Track Status for DLBCL Treatment

News

The U.S. Food and Drug Administration has granted fast track status to Karyopharm Therapeutics‘ investigational oral therapy selinexor for people with diffuse large B-cell lymphoma (DLBCL) who have received two or ... Read more

November 9, 2018

Seattle Genetics Seeks Adcetris Approval as First-Line Combo Treatment for Peripheral T-cell Lymphomas

News

Seattle Genetics has asked the U.S. Food and Drug Administration (FDA) to expand the label for Adcetris (brentuximab vedotin) to be used in combination with chemotherapy as a first-line treatment for patients ... Read more

November 6, 2018

Adcetris as Stem Cell Transplant Consolidation Therapy Delays Hodgkin’s Progression in Long-term, Data Show

News

Patients with classical Hodgkin’s lymphoma who are at high risk of progressing after a stem cell transplant may benefit significantly from Adcetris (brentuximab vedotin) consolidation treatment in the long-term, researchers ... Read more

November 5, 2018

Imbruvica Combo Improves Long-term Survival in CLL/SLL Patients, Updated Phase 3 Results Show

News

Combining AbbVie’s Imbruvica (ibrutinib) with Treanda (bendamustine) and Rituxan (rituximab) improves long-term survival outcomes in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) whose cancer reappeared ... Read more

November 5, 2018

MK-1454/Keytruda Combination Shows Promise in Solid Tumor and Lymphoma Patients

News

A combination of the investigational agent MK-1454 and Keytruda (pembrolizumab) induced robust and durable responses in solid tumor and lymphoma patients in a Phase 1 trial, Merck (known as MSD outside ... Read more

Pin It on Pinterest